Exploring predictive biomarkers for lenvatinib and pembrolizumab response in endometrial cancer patients, including NLR, CD20+ B cells, and KEYNOTE-146 findings.
Groundbreaking discovery reveals why breast cancer survivors face increased risk of aggressive endometrial cancer and what this means for genetic counseling and future care.